GlassScriptPhysician profile
Kameswara Ran Tatineni
NPI 1700977154
$99,251.92
in general payments reported to CMS, 2019-2025
33 companies · $3,887 in 2025
The $3,887 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $15K · 2021: $17K · 2022: $12K · 2023: $12K · 2024: $11K · 2025: $3,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,581 · Travel and Lodging: $1,568 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,150.00 |
| Food and Beverage | $9,580.55 |
| Travel and Lodging | $1,567.80 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $31,234.40 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25,633.43 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $18,016.89 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $6,068.35 | 2019-2022 | |
| Allergan, INC. | $5,845.32 | 2019-2020 | |
| Alkermes, INC. | $3,047.75 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,993.16 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,476.76 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $910.42 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $839.60 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $733.29 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $539.63 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $517.25 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $515.85 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $432.16 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $314.17 | 2019-2025 | Zubsolv |
| Indivior INC. | $164.11 | 2019-2024 | Perseris |
| Corium, LLC | $158.68 | 2022 | |
| Braeburn INC. | $144.16 | 2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $126.88 | 2019-2022 | |
| Eisai INC. | $119.78 | 2020-2021 | |
| Noven Therapeutics, LLC | $96.71 | 2024 | Secuado, Xelstrym |
| Neuronetics, INC. | $70.56 | 2019-2020 | |
| Shire North American Group INC | $38.28 | 2019 | |
| Insmed, INC. | $34.32 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| Adlon Therapeutics L.P. | $30.55 | 2020-2021 | |
| Sage Therapeutics, LLC | $30.34 | 2022 | |
| Janssen Biotech, INC. | $23.56 | 2023 | |
| Uswm, LLC | $18.04 | 2022 | |
| Merck Sharp & Dohme LLC | $16.90 | 2021 | |
| Kaleo, INC. | $16.60 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kameswara Tatineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.